Following the 2025 NHIA Conference in Washington D.C., Bailey Klingaman shares a brief recap of the latest news for home infusion. From market developments to events at the conference to updates on advocacy efforts, this article covers relevant news and details the home infusion and pharmacy industries.
The National Home Infusion Association (NHIA) finished up another successful conference a few weeks ago in Washington D.C. After last year’s record breaking attendance, they kept the momentum going with the 2025 NHIA Conference and featured 150 companies showcasing their products and services, and 1,600 home and alternate site infusion professionals, according to a recent report from NHIA. The conference lasted four days and included networking events, educational sessions, exhibitors, and more.
Recently in the Home Infusion Industry
From projected market growth to updates on Medicare Part D programs, the infusion and healthcare industries are predicting significant changes over the next few months and years.
Market Growth
In last year’s recap of the NHIA Conference, the global home infusion market was projected to reach $64.56 billion by 2030. This year’s report from Precedence Research anticipates a market of $84.6 billion by 2034, with a compound annual growth rate (CAGR) of 8.14% from 2025 to 2034.
So far, North America has dominated home infusion with approximately 56% of the market, but Asia Pacific is projected to lead the growth over the next few years. This is due to an increase in diabetes and the prevalence of ongoing illness in the geriatric population of the area.
Infusion in the News
In addition to market growth, there have been other notable developments in the home infusion therapy sector, including new reports from the Centers for Medicare & Medicaid Services (CMS) and changes to Medicare Part D programs.
Medicare Part D Benefit Design & Payment
As of January 2025, Medicare Part D beneficiaries will have a maximum out-of-pocket cap on drug costs of $2,000. The excess costs are shifted off of the patients and federal government, per the Inflation Reduction Act (IRA), and onto the drug manufacturers.
In addition, the base beneficiary Part D premium as of 2025 is $36.78 a month and the base premiums are capped at an annual growth rate of 6%. Monthly premiums for individual plans and base premiums do differ, so actual monthly premiums may vary depending on the beneficiary’s plan.
The IRA has also introduced the Medicare Prescription Payment Plan (MPPP). This allows enrollees to disperse the annual $2,000 out-of-pocket costs into monthly payments.
Pharmaceutical Tariffs
On April 9th, the Trump Administration announced a baseline 10% tariff on imported goods from all countries and a 125% tariff on goods imported from China. As of the 9th, this tariff does not yet apply to pharmaceutical products. However, President Trump suggested that this is likely to change and that “major” tariffs on drug imports are coming. According to the announcement, these pharmaceutical tariffs are intended to incentivize an increase in domestic drug manufacturing.
2025 NHIA Conference
Tennr, WeInfuse & RxToolKit Welcome Party
To kickstart the 2025 NHIA Conference, RxToolKit partnered with WeInfuse and Tennr to throw a conference welcome party. On Sunday, March 29th, our three teams assembled at The Brass Tap – National Harbor right down the road from the conference hall to set up for the party of the weekend.
Equipped with music, food, signature drinks, a photo booth, and beer pong, the party was a hit. Beer pong players were awarded custom party pins as a token to thank them for coming and congratulate them on their pong skills. But the party wasn’t just about the pong and drinks—there was lots of networking, introductions, important chats, and memories being made.
Exhibiting at NHIA
The RxToolKit team spent the next few days in the exhibit hall showing off our infusion medication information and clinical training platforms, and building relationships with the attendees and other exhibitors.
If you weren’t able to stop by the RxToolKit booth or chat with our team outside of exhibiting hours, we would still love to talk. Give us a call at (888)798-5548, email us at sales@rxtoolkit.com, or stay up-to-date with our social media (all accounts – @rxtoolkit).
See what WeInfuse was up to at the 2025 NHIA Conference in their “NHIA 2025 WeInfuse & RxToolKit Recap” blog.
Market Entry & Expansion: Get in Where You Fit In
On the last day of the 2025 NHIA Conference, WeInfuse Pharmacist Operations Specialist Justin Whitsett held an educational session with Geisinger Director of Pharmacy Strategy Kristin Kruszewski on entering the infusion market.
The objectives of the session were to (1) inform operational leadership of the characteristics and considerations necessary to effectively enter or expand into infusion markets, (2) to supply attendees with an understanding of the partnerships available to support their infusion businesses and clinical services, and (3) showcase the importance and impact of infusion services for patients, providers, and healthcare systems.
Interested in entering or expanding your current clinical services into the infusion market? WeInfuse’s consulting services can help you navigate the complicated infusion landscape, and provide a suite of services to help you succeed. Explore these resources to learn more about opening an infusion center:
- Considerations for Opening an In-Office Infusion Center – Blog by WeInfuse CEO Bryan Johnson
- Starting an Infusion Center in Your Practice – Blog by WeInfuse CEO Bryan Johnson
- Key Ingredients to a Successful Infusion Practice – Podcast Episode with WeInfuse COO Reece Norris
What’s Next for Home Infusion
Advocacy
There’s no doubt that it has been an eventful start to 2025 for the home infusion and pharmacy industry, and it doesn’t appear to be slowing down any time soon. In addition to hosting the NHIA Conference and coordinating the numerous events and forums that accompany the symposium, the National Home Infusion Association has been busy advocating for those in the industry.
Joe Fiandra Access to Home Infusion Act (H.R. 5397)
Last year, we discussed the Joe Fiandra Access to Home Infusion Act and the intentions of the bill: to expand the drugs and biologics under the Part B Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) external infusion pump benefit by “modifying the ‘appropriate for use in the home’ requirement for durable medical equipment,” assuming they meet the following criteria:
- The FDA prescribing information instructs that the drug associated with the pump should be administered by or under the supervision of a healthcare professional.
- A home infusion supplier either administers or supervises the administration in the patient’s home.
- The FDA prescribing information instructs that the drug be infused either at least 12 times per year or at infusion rates that would require an external pump.
While NHIA was not originally in support of the bill, they expressed further concerns in the Nov./Dec. 2024 issue of INFUSION Magazine, stating, “…expanding coverage under the Fiandra bill appears less advantageous now than when it was first conceived.”
Due to the recent changes in 2025 to Medicare Part D that makes it a “more desirable” option over Part B, NHIA says, “…expanding coverage in a benefit that beneficiaries can’t afford to use does nothing to improve access to much-needed therapies.” NHIA warns against passing the Fiandra bill without also passing the Preserving Patient Access to Home Infusion Act to protect patients that rely on home infusion therapy.
Preserving Patient Access to Home Infusion Act (H.R. 4101, S. 1976)
Also a feature in last year’s recap of the 2025 NHIA Conference, the Preserving Patient Access to Home Infusion Act is expressly endorsed by NHIA.
According to a press release about the bill, the implementation of the benefit for Medicare Part B home infusion drugs improperly requires a nurse to be physically present for providers to be reimbursed for home infusion therapy medications. This has resulted in a decline in participation in Medicare’s home infusion benefit and reduced access to home infusion therapy for patients in need.
The Preserving Patient Access to Home Infusion Act would:
- Require CMS to pay home infusion providers for professional services each day the drug is administered.
- Remove the requirement that a skilled professional be present in the home for billing to occur.
- Define the covered pharmacy professional services.
NHIA is currently running a grassroots letter writing campaign in support of the act, and urges NHIA members to reach out to their Congress members. As of November 2024, the act had a group of more than 35 patient and stakeholder groups advocating for implementation.
Infusion & Pharmacy Software
In addition to exhibiting at the 2025 NHIA Conference and co-hosting a party to network with home infusion and pharmacy leaders, RxToolKit and WeInfuse also brought groundbreaking software solutions to the industry.
WeInfuse
WeInfuse’s infusion workflow management solution has expanded to include a complete pharmacy solution, which includes “easy-to-use features for automated PDMP reporting, dashboard monitoring, label customization, supply and preparation instruction templating, real-time inventory & supplies tracking, and more.”
RxToolKit
RxToolKit includes two solutions in one software package: RxWorkFlow and RxELearning.
The RxWorkFlow platform contains an online library of over 300 user-friendly medication guides designed and maintained by a team of clinicians. Accompanied by drug-specific calculators, printable patient education resources, and safety data sheets, each guide distills the lengthy medication package insert into an easy-to-navigate monograph with informative graphics, quick links, and personal note-taking abilities for users.
The RxELearning platform offers training and drug-specific assessments for clinicians to enhance medication competency. Clinical managers have the option to assign specialty-driven Learning Paths to users and follow course progression, while receiving competency verification reporting. RxELearning also includes continuing education (CE) and continuing medical education (CME) units provided by the Infusion Nurses Society and the Immunoglobulin National Society.
Where to Find Us Next
Couldn’t get enough at the 2025 NHIA Conference or weren’t able to attend?
RxToolKit will also be exhibiting at the upcoming 2025 Infusion Nurses Society (INS) Annual Meeting in Las Vegas and the 2025 National Infusion Center Association (NICA) Conference in Miami. We’ll be attending the annual TOAST: Together for Treatment event hosted by the Infusion Access Foundation (IAF) before the NICA Conference, and we hope to see you there!
